Pfizer Inc. $PFE Stock Sold by Hennessy Advisors Inc.

Hennessy Advisors Inc. lessened its stake in Pfizer Inc. (NYSE:PFE) by 22.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 228,900 shares of the biopharmaceutical company’s stock after selling 67,213 shares during the quarter. Hennessy Advisors Inc.’s holdings in Pfizer were worth $6,528,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. increased its position in shares of Pfizer by 15.7% during the second quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock worth $132,365,000 after purchasing an additional 745,213 shares in the last quarter. Handelsbanken Fonder AB lifted its holdings in Pfizer by 10.4% in the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock valued at $59,295,000 after purchasing an additional 232,528 shares in the last quarter. Leuthold Group LLC purchased a new position in Pfizer in the 2nd quarter valued at $4,887,000. Park National Corp OH boosted its stake in Pfizer by 332.1% during the 2nd quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock worth $5,829,000 after purchasing an additional 186,053 shares during the last quarter. Finally, 111 Capital acquired a new stake in Pfizer during the 2nd quarter worth $3,706,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met its primary endpoint in patients with relapsed or refractory multiple myeloma. The result supports another potential growth driver for Pfizer’s oncology portfolio. The FDA also expanded the use of TALZENNA plus XTANDI for certain men with metastatic hormone-sensitive prostate cancer, increasing the commercial opportunity for the combination. Pfizer cancer trial and FDA approval article
• Positive Sentiment: New real-world data from China showed continued momentum for lorlatinib in lung cancer treatment, potentially reinforcing the drug’s adoption and durability outside clinical-trial settings. Lorlatinib China study article
• Positive Sentiment: Pfizer launched a Phase 1 trial for Alzheimer’s candidate PF-08161842, adding a new early-stage asset to its pipeline. Although the program is years from potential commercialization, it gives investors another source of long-term optionality. PF-08161842 Alzheimer’s trial article
• Neutral Sentiment: Investors are focused on Pfizer’s third-quarter earnings report, scheduled for November 3. Attention will center on whether non-COVID products and pipeline progress can offset continuing declines in pandemic-related revenue. Pfizer Q3 earnings outlook article
• Negative Sentiment: Analysts remain cautious ahead of earnings, while commentary highlights that Pfizer’s nearly 6% dividend yield exceeded free cash flow in the prior year. That raises questions about long-term payout coverage, even though the dividend remains attractive to income-focused investors. Pfizer dividend safety article

Analyst Upgrades and Downgrades

PFE has been the subject of a number of recent research reports. JPMorgan Chase & Co. increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 9th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Bank of America cut their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, October 13th. Finally, BMO Capital Markets lowered their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Five analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $28.65.

Pfizer Price Performance

PFE stock opened at $30.48 on Monday. The business’s 50-day moving average is $28.55 and its two-hundred day moving average is $26.79. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The firm has a market capitalization of $173.73 billion, a P/E ratio of 40.11, a P/E/G ratio of 2.07 and a beta of 0.31. Pfizer Inc. has a 1 year low of $23.62 and a 1 year high of $30.67.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the previous year, the company posted $0.78 earnings per share. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 5.6%. The ex-dividend date is Friday, November 6th. Pfizer’s payout ratio is 226.32%.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.